Jaffetilchin Investment Partners LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 10.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,995 shares of the company’s stock after selling 357 shares during the quarter. Jaffetilchin Investment Partners LLC’s holdings in Johnson & Johnson were worth $418,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the business. Landmark Financial Advisors LLC lifted its stake in Johnson & Johnson by 0.4% in the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after acquiring an additional 7 shares during the last quarter. Paradigm Financial Advisors LLC lifted its stake in Johnson & Johnson by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock valued at $350,000 after acquiring an additional 9 shares during the last quarter. Premier Asset Management LLC raised its position in shares of Johnson & Johnson by 0.4% in the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after purchasing an additional 12 shares during the period. Lbmc Investment Advisors LLC raised its position in shares of Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock valued at $492,000 after purchasing an additional 14 shares during the period. Finally, Halbert Hargrove Russell LLC raised its position in shares of Johnson & Johnson by 0.4% in the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock valued at $466,000 after purchasing an additional 15 shares during the period. Hedge funds and other institutional investors own 67.21% of the company’s stock.
Johnson & Johnson stock opened at $131.19 on Thursday. Johnson & Johnson has a 1 year low of $120.95 and a 1 year high of $148.32. The company has a market cap of $352,023.59, a PE ratio of 17.97, a P/E/G ratio of 2.09 and a beta of 0.77. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The business had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same period last year, the firm earned $1.58 earnings per share. Johnson & Johnson’s revenue for the quarter was up 11.5% compared to the same quarter last year. analysts anticipate that Johnson & Johnson will post 8.11 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th were given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date was Monday, February 26th. Johnson & Johnson’s dividend payout ratio is 861.54%.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.19% of the stock is currently owned by company insiders.
JNJ has been the topic of several research analyst reports. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Monday, January 22nd. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Wells Fargo reissued an “outperform” rating and issued a $160.00 price objective (up from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Finally, JPMorgan Chase & Co. lowered shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $146.26.
ILLEGAL ACTIVITY NOTICE: This report was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://ledgergazette.com/2018/03/22/johnson-johnson-jnj-holdings-reduced-by-jaffetilchin-investment-partners-llc.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.